Skip to main content

Table 1 Correlation between eIF4A1 expression and clinical characteristics of PDAC patients

From: Targeted intervention of eIF4A1 inhibits EMT and metastasis of pancreatic cancer cells via c-MYC/miR-9 signaling

Clinical characteristics High-eIF4A1 Low-eIF4A1 P-value
Age, mean ± SD, years 66.04 ± 9.69 64.10 ± 10.07 0.482
Male, n (%) 13 (56.53%) 21 (70.00%) 0.311
Overall survival, median, months 6.0 (4.0, 9.0) 9.0 (8.0, 15.5) 0.006b
Differentiation status   0.523
 Well differentiated 11 (20.75%) 17 (32.08%)  
 Moderately to poorly differentiated 12 (22.64%) 13 (24.53%)
Tumor size, mean ± SD, cm 4.57 ± 1.40 3.75 ± 1.28 0.032b
Recurrences, n (%) 17 (73.91%) 20 (66.67%) 0.569
Location   0.267
 Head, n (%) 15 (28.30%) 18 (33.96%)  
 Body/tail, n (%) 7 (13.21%) 20 (37.74%)
Diffusion involvement, n (%) 1 (1.89%) 2 (3.77%)
TNM stagea   0.077
 I–II stage, n (%) 14 24  
 III–IV stage, n (%) 9 5
Lymph node metastasis, n (%) 14 (63.64%) 10 (35.71%) 0.0498*
Vascular Infiltration, n (%) 10 (43.48%) 3 (10.00%) 0.272
  1. aNCCN Version 3.2019 pancreatic adenocarcinoma
  2. bP < 0.05, significant difference